Pharmacological aspects of the safety of gliflozins - PubMed (original) (raw)
Review
Pharmacological aspects of the safety of gliflozins
Jean-Luc Faillie. Pharmacol Res. 2017 Apr.
Abstract
Sodium-glucose transporter 2 (SGLT2) inhibitors, also known as gliflozins, are a new class of orally active drugs used in the management of type 2 diabetes. By inhibiting the SGLT responsible for the reabsorption of glucose from the kidney, their use aims primarily to induce glycosuria and, as a consequence, lower glycemic levels. However, their specific mechanism of action involves other pharmacodynamic consequences including potentially harmful adverse reactions. This manuscript reviews the physiological and pharmacological background behind inhibition of SGLTs, and discusses the pharmacological aspects of the safety of gliflozins.
Keywords: Adverse reactions; Canagliflozin (PubChem CID: 24812758); Dapagliflozin (PubChem CID: 9887712); Drug safety; Empagliflozin (PubChem CID: 11949646); Ipragliflozin (PubChem CID: 10453870); Phlorizin(PubChem CID: 6072); SGLT2 inhibitors; Sodium-glucose transporters; Tofogliflozin (PubChem CID: 46908929); Type 2 diabetes.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
- Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T, Fukazawa M, Honda K, Yata T, Kawai M, Yamane M, Murao N, Yamaguchi K, Kato M, Mitsui T, Suzuki Y, Ikeda S, Kawabe Y. Nagata T, et al. Am J Physiol Endocrinol Metab. 2013 Feb 15;304(4):E414-23. doi: 10.1152/ajpendo.00545.2012. Epub 2012 Dec 18. Am J Physiol Endocrinol Metab. 2013. PMID: 23249697 - Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective.
Madaan T, Akhtar M, Najmi AK. Madaan T, et al. Eur J Pharm Sci. 2016 Oct 10;93:244-52. doi: 10.1016/j.ejps.2016.08.025. Epub 2016 Aug 12. Eur J Pharm Sci. 2016. PMID: 27531551 Review. - Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling.
Sokolov V, Yakovleva T, Chu L, Tang W, Greasley PJ, Johansson S, Peskov K, Helmlinger G, Boulton DW, Penland RC. Sokolov V, et al. CPT Pharmacometrics Syst Pharmacol. 2020 Apr;9(4):222-229. doi: 10.1002/psp4.12498. Epub 2020 Mar 6. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 32064793 Free PMC article. - In brief: ketoacidosis with SGLT2 inhibitors.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2015 Jun 22;57(1471):94. Med Lett Drugs Ther. 2015. PMID: 26079766 No abstract available.
Cited by
- Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients With Type 2 Diabetes and the Incidence of Retinal Vein Occlusion in Taiwan.
Tsai HR, Lin YJ, Yeh JI, Lin SM, Liu PP, Chang YC, Lee YC, Loh CH, Huang HK. Tsai HR, et al. Invest Ophthalmol Vis Sci. 2024 Jun 3;65(6):19. doi: 10.1167/iovs.65.6.19. Invest Ophthalmol Vis Sci. 2024. PMID: 38864813 Free PMC article. - Glycomimetics and Glycoconjugates in Drug Discovery.
Xavier NM, Andreana PR. Xavier NM, et al. Pharmaceuticals (Basel). 2024 Mar 1;17(3):323. doi: 10.3390/ph17030323. Pharmaceuticals (Basel). 2024. PMID: 38543110 Free PMC article. - The Reasons for the Low Uptake of New Antidiabetic Drugs with Cardiovascular Effects-A Family Doctor Perspective.
Kurevija T, Šojat D, Bosnić Z, Mujaj B, Canecki Varžić S, Majnarić Trtica L. Kurevija T, et al. J Clin Med. 2024 Mar 12;13(6):1617. doi: 10.3390/jcm13061617. J Clin Med. 2024. PMID: 38541843 Free PMC article. Review. - Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter.
Hiraizumi M, Akashi T, Murasaki K, Kishida H, Kumanomidou T, Torimoto N, Nureki O, Miyaguchi I. Hiraizumi M, et al. Nat Struct Mol Biol. 2024 Jan;31(1):159-169. doi: 10.1038/s41594-023-01134-0. Epub 2023 Dec 6. Nat Struct Mol Biol. 2024. PMID: 38057552 Free PMC article. - Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Chen L, Xue Q, Yan C, Tang B, Wang L, Zhang B, Zhao Q. Chen L, et al. Front Endocrinol (Lausanne). 2023 Nov 10;14:1256548. doi: 10.3389/fendo.2023.1256548. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38027214 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical